Cargando…

Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour

BACKGROUND: In xeroderma pigmentosum (XP), the main means of preventing skin and eye cancers is extreme protection against ultraviolet radiation (UVR). Protection is most important for the face. OBJECTIVES: We aimed to assess how well patients with XP adhere to medical advice to protect against UVR...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkany, R.P.E., Canfield, M., Morgan, M., Foster, L., Johnstone, K., Sainsbury, K., Araujo‐Soares, V., Wulf, H.C., Weinman, J., Walburn, J., Norton, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306996/
https://www.ncbi.nlm.nih.gov/pubmed/34783007
http://dx.doi.org/10.1111/bjd.20899
_version_ 1784752669478354944
author Sarkany, R.P.E.
Canfield, M.
Morgan, M.
Foster, L.
Johnstone, K.
Sainsbury, K.
Araujo‐Soares, V.
Wulf, H.C.
Weinman, J.
Walburn, J.
Norton, S.
author_facet Sarkany, R.P.E.
Canfield, M.
Morgan, M.
Foster, L.
Johnstone, K.
Sainsbury, K.
Araujo‐Soares, V.
Wulf, H.C.
Weinman, J.
Walburn, J.
Norton, S.
author_sort Sarkany, R.P.E.
collection PubMed
description BACKGROUND: In xeroderma pigmentosum (XP), the main means of preventing skin and eye cancers is extreme protection against ultraviolet radiation (UVR). Protection is most important for the face. OBJECTIVES: We aimed to assess how well patients with XP adhere to medical advice to protect against UVR by objectively estimating the mean daily dose of UVR to the face. METHODS: We objectively estimated the UVR dose to the face in 36 patients with XP and 25 healthy individuals over 3 weeks in the summer. We used a new methodology which combined UVR dose measurements from a wrist‐worn dosimeter with an activity diary record of face photoprotection behaviour for each 15‐min period spent outside. A protection factor was associated with each behaviour, and the data were analysed using a negative binomial mixed‐effects model. RESULTS: The mean daily UVR dose (weighted for DNA damage capacity) to the face in the patients with XP was 0·13 standard erythemal doses (SEDs) (mean in healthy individuals = 0·51 SED). There was wide variation between patients (range < 0·01–0·48 SED/day). Self‐caring adult patients had a very similar UVR dose to the face as cared‐for patients (0·13 vs. 0·12 SED/day), despite photoprotecting much more poorly when outside, because the self‐caring adults were outside in daylight much less. CONCLUSIONS: Photoprotection behaviour varies widely within the XP group indicating that nonadherence to photoprotection advice is a significant issue. The timing and duration of going outside are as important as photoprotective measures taken when outside, to determine the UVR exposure to the face. This new methodology will be of value in identifying the sources of UVR exposure in other conditions in which facial UVR exposure is a key outcome, particularly in patients with multiple nonmelanoma skin cancers.
format Online
Article
Text
id pubmed-9306996
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93069962022-07-28 Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour Sarkany, R.P.E. Canfield, M. Morgan, M. Foster, L. Johnstone, K. Sainsbury, K. Araujo‐Soares, V. Wulf, H.C. Weinman, J. Walburn, J. Norton, S. Br J Dermatol Original Articles BACKGROUND: In xeroderma pigmentosum (XP), the main means of preventing skin and eye cancers is extreme protection against ultraviolet radiation (UVR). Protection is most important for the face. OBJECTIVES: We aimed to assess how well patients with XP adhere to medical advice to protect against UVR by objectively estimating the mean daily dose of UVR to the face. METHODS: We objectively estimated the UVR dose to the face in 36 patients with XP and 25 healthy individuals over 3 weeks in the summer. We used a new methodology which combined UVR dose measurements from a wrist‐worn dosimeter with an activity diary record of face photoprotection behaviour for each 15‐min period spent outside. A protection factor was associated with each behaviour, and the data were analysed using a negative binomial mixed‐effects model. RESULTS: The mean daily UVR dose (weighted for DNA damage capacity) to the face in the patients with XP was 0·13 standard erythemal doses (SEDs) (mean in healthy individuals = 0·51 SED). There was wide variation between patients (range < 0·01–0·48 SED/day). Self‐caring adult patients had a very similar UVR dose to the face as cared‐for patients (0·13 vs. 0·12 SED/day), despite photoprotecting much more poorly when outside, because the self‐caring adults were outside in daylight much less. CONCLUSIONS: Photoprotection behaviour varies widely within the XP group indicating that nonadherence to photoprotection advice is a significant issue. The timing and duration of going outside are as important as photoprotective measures taken when outside, to determine the UVR exposure to the face. This new methodology will be of value in identifying the sources of UVR exposure in other conditions in which facial UVR exposure is a key outcome, particularly in patients with multiple nonmelanoma skin cancers. John Wiley and Sons Inc. 2022-02-24 2022-04 /pmc/articles/PMC9306996/ /pubmed/34783007 http://dx.doi.org/10.1111/bjd.20899 Text en © 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Sarkany, R.P.E.
Canfield, M.
Morgan, M.
Foster, L.
Johnstone, K.
Sainsbury, K.
Araujo‐Soares, V.
Wulf, H.C.
Weinman, J.
Walburn, J.
Norton, S.
Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
title Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
title_full Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
title_fullStr Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
title_full_unstemmed Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
title_short Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
title_sort ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306996/
https://www.ncbi.nlm.nih.gov/pubmed/34783007
http://dx.doi.org/10.1111/bjd.20899
work_keys_str_mv AT sarkanyrpe ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT canfieldm ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT morganm ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT fosterl ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT johnstonek ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT sainsburyk ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT araujosoaresv ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT wulfhc ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT weinmanj ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT walburnj ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour
AT nortons ultravioletradiationexposuretothefaceinpatientswithxerodermapigmentosumandhealthycontrolsapplyinganovelmethodologytodefinephotoprotectionbehaviour